secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031624
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR
--------------------------------------------------------------------------------

- Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
- Net loss $51M ($0.46/ADS); operating loss $69.4M; cash $761.3M at March 31.
- Zoci (DLL3 ADC) delivered 62.5% confirmed intracranial ORR in SCLC brain mets at AACR; 38.2% ORR in epNECs.
- Clinical collaborations with Amgen and Boehringer Ingelheim to evaluate zoci combinations in SCLC and NECs.
- Appointed Yizhe Wang, Ph.D., as Operating Partner; KarXT launch preparations underway; TIVDAK under regulatory review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/0001628280-26-031624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer